Clinical Advancements in HIV Education Center

According to the CDC, a significant proportion of patients who know they are infected with HIV and are prescribed antiretroviral therapy (ART) do not attain adequate virologic and immunologic responses due to treatment burdens, including poor retention in care, nonadherence, unfavorable pharmacokinetics, or other biologic or socioeconomic factors. However, research and treatment advances aimed at reducing pill-burden, treatment resistance, proactive prevention, early detection, and rapid treatment initiation are changing how HIV is treated.

This Education Center is intended to update clinicians on the latest developments in HIV research and treatment in order to help them manage patients with the disease.

Most PrEP Prescriptions Are Being Written by Primary Care Physicians

Most PrEP Prescriptions Are Being Written by Primary Care Physicians

The most common prescriber of preexposure prophylaxis (PrEP) for HIV is primary care physicians, according to recent data from a Medicare database published as a Research Letter in JAMA...
FDA Approves Fostemsavir For HIV Treatment

FDA Approves Fostemsavir For HIV Treatment

The FDA has approved a new treatment for HIV-1 patients who are failing their current therapy...
FDA Approves Dispersible Tablet Treatment for HIV

FDA Approves Dispersible Tablet Treatment for HIV

The FDA has approved dolutegravir as the first dispersible tablet for children living with HIV, according to a press release from the manufacturer...
HIV Associated with Increased Bone Fracture Risk

HIV Associated with Increased Bone Fracture Risk

People living with HIV have a higher prevalence and incidence of bone fractures than the general population, a systematic review and meta-analysis suggests...
 
Researchers Develop Version of Cabotegravir That Can Last Up to 1 Year

Researchers Develop Version of Cabotegravir That Can Last Up to 1 Year

A new version of the integrase inhibitor cabotegravir has been developed into a nanoformulated prodrug that could soon be a once-yearly treatment for people living with HIV-1...

Loading...

© 2020 /alert® unless otherwise noted. All rights reserved.
Reproduction in whole or in part without permission is prohibited.
Privacy Policy | Terms of Use
Do Not Sell My Personal Information